Dr Fletcher is a respiratory, general medicine and intensive care medicine consultant with a sub-specialty interest in respiratory critical care and interstitial lung disease.

BA BM BCh MRCP PG Cert (Med Ed)

Training and education

BA medical science tripos - Queens’ College, Cambridge University, 1995
BM BCh - Magdalen College, Oxford University, 2001
Postgraduate training - St Thomas’ Hospital London and The Royal Brompton London, 2004
Higher specialist training in respiratory, general and intensive care - Wessex deanery, 2012

Experience

Sophie Fletcher is an active member of the the ILD (Interstitial Lung Disease) clinical service, a regional specialist service recognised by NHS England, a service that receives both national and international referrals.

Dr Fletcher was worked with the British Lung Foundation, the biomedical research unit, the University of Southampton and Portsmouth hospital to set up a patient support group for those in Wessex with ILD – WILD,

www.wildsupport.co.uk

Dr Fletcher is an Honorary Senior clinical lecturer at the University of Southampton and has extensive experience of leading clinical trials in Interstitial lung disease both as a Principle Investigator and Chief Investigator and has published her work in peer reviewed journals and presented at both national and international conferences. She has established an international ILD clinical research fellowship programme at UHS.

Dr Fletcher has been the clinical lead for the Respiratory Department at UHS from 2018-2020 including the COVID 19 global pandemic. She is the PI for the RECOVERY trial at UHS and a member of the COVID guidelines committee.

Dr Fletcher is the module Lead for medicine – final year – supported by the University of Southampton

Awards and prizes

Awarded a place on the Research Leaders Programme – in recognition of ongoing clinical patient facing research in ILD, supported by UHS
The ILD research team following their collaborative work with the patient support group ‘WILD’ were shortlisted for a Nursing Times award in the category ‘Respiratory Nursing’. ILD research team are nominated for the ‘Hospital hero’ awards at UHS - March 2019.

Research

Rituximab compared to intravenous Cyclophosphamide in Connective Tissue Disease associated Interstitial Lung Disease (RECITAL): a randomised controlled clinical trial. Toby M Maher PhD, Veronica Tudor PhD, Peter Saunders PhD, Michael A Gibbons PhD, Sophie V Fletcher MD, Christopher P Denton PhD, Rachel K Hoyles PhD, Helen Parfrey PhD, Elisabetta A Renzoni PhD, Maria Kokosi MD, Athol U Wells MD, Deborah Ashby PhD, Matyas Sziget PhD, Philip L Molyneaux PhD; on behalf of the RECITAL investigators. Lancet Respiratory Medicine. Published online November 11, 2022 https://doi.org/10.1016/S2213-2600(22)00359-9
Luca Richeldi, Sophie Fletcher, Huzaifa Adamali, Nazia Chaudhuri, Sabrina Wieb, Sven Wind, Kathrin Hohl, Andrew Baker, Rozsa Schlenker-Herceg, Susanne Stowasser, Toby M. Maher. No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone. Eur Respir J 2019.
Giacomo Sgalla; Simon Walsh; Nicola Sverzellati; Sophie Fletcher; Stefania Cerri; Borislav Dimitrov; Dragana Nikolic; Anna Barney; Fabrizio Luppi; Mark Jones; Donna Davies; Luca Richeldi. "Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease BMC Pulmonary Medicine 2018;18:103
Fletcher S, Jones MG, Spinks K, Sgalla G, Marshall BG, Limbrey R, Richeldi L. The safety of new drug treatments for Idiopathic Pulmonary Fibrosis. Expert Opinion Drug Safety 2016; 15:1483-1489.

Dr Fletcher's main research interests are Idiopathic Pulmonary Fibrosis (IPF) and interstitial lung disease, as well as critical care medicine and non-invasive ventilation.

For further details on Dr Fletcher's research please visit, Sophie Fletcher (nihr.ac.uk)

Contact

You can contact Dr Fletcher via her secretary Hayley King - call 023 8120 6228 or send an email.